BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 12.154
- Punti reazioni
- 1.266
Tra poco ci sarà questa Call, vediamo cosa ne viene fuori
Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
GlobeNewswire GlobeNewswire•March 24, 2020
Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus
LOS ANGELES, March 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that it will host a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on Thursday, March 26, 2020 at 12pm Eastern Time.
The call will feature a presentation by KOL and newly appointed Capricor Executive Consultant Stephen J. Gould, Ph.D., from Johns Hopkins University, who will provide an overview of an exosome-based vaccine approach. Additionally, he will discuss the strategic plan to further develop the company's exosome platform technologies including its potential application as a COVID-19 vaccine. Capricor is committed to developing precision-engineered exosomes that carry defined sets of effector molecules which exert their effects through defined mechanisms of action.
Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
GlobeNewswire GlobeNewswire•March 24, 2020
Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus
LOS ANGELES, March 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that it will host a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on Thursday, March 26, 2020 at 12pm Eastern Time.
The call will feature a presentation by KOL and newly appointed Capricor Executive Consultant Stephen J. Gould, Ph.D., from Johns Hopkins University, who will provide an overview of an exosome-based vaccine approach. Additionally, he will discuss the strategic plan to further develop the company's exosome platform technologies including its potential application as a COVID-19 vaccine. Capricor is committed to developing precision-engineered exosomes that carry defined sets of effector molecules which exert their effects through defined mechanisms of action.
